Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPI-145 first-in-human randomized double-blind placebo-controlled SAD/MAD study in healthy adults
NL-OMON35436Phase 1Active, not recruiting
- Sponsor
- Infinity Pharmaceuticals, Inc.
- Start
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Inflammatory Disorders and hematopoietic malignancies comparing IPI-145 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Jul 2011; status: active, not recruiting.
02
Drugs
duvelisib
03
Conditions
Inflammatory Disordershematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON35436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35436.